[Surgical treatment of pulmonary tuberculosis complicated with aspergilloma].

OBJECTIVE: To investigate the surgical indications of pulmonary tuberculosis complicated with aspergilloma , and to reduce postoperative complications. METHODS: From 1993 to 2010, a total of 51 surgically treated patients in pulmonary tuberculosis complicated with aspergilloma were analyzed retrospectively. The common surgical procedure performed was lobectomy(60.8%), followed by segmentectomy(15.7%), pneumonectomy(9.8%), wedge resection(9.8%). RESULTS: Postoperative non-fatal complications occurred in all patients, the complications (13 cases) included postoperative atelectasis(7.8%), bleeding(5.9%), bronchopleural fistula(5.9%), cardiac arrhythmia and heart failure(2.0%), incisional infection(2.0%). CONCLUSIONS: Surgical treatment of pulmonary tuberculosis complicated with aspergilloma is the most effective treatment; pulmonary resection is the treatment of choice when indicated.

[Study of prognostic factors in patients with stage I non-small cell lung cancer].

OBJECTIVE: To analyze the prognostic factors for patients with stage I non-small cell lung cancer. METHODS: A total of 224 patients with stage I non-small cell lung cancer operated from 1999 to 2004 were retrospectively reviewed. The clinical profiles of age, gender, T grade, type of resection, tumor pathological typing, tumor cell differentiation and post-operative chemotherapy were analyzed by SPSS 13.0 statistic software. RESULTS: The five-year survival of stages Ia and Ib non-small cell lung cancer were 78.7% and 51.5% respectively. In univariate analysis, T grade and tumor cell differentiation were independent prognostic factors respectively. In multivariate analysis, T grade and tumor cell differentiation were independent prognostic factors for overall survival. CONCLUSION: There are significant differences in the five-year survival of stages Ia and Ib non-small lung cancer. Both tumor stage and tumor cell differentiation were independent prognostic factor for overall survival.

[Second-line Hycamtin in the treatment of lung cancer].

OBJECTIVE: To discuss the therapeutic effect and toxicity of second line Hycamtin for lung cancer patients. METHODS: Ten of these 21 patients had been treated with operation. All these 21 patients received second line Hycamtin treatment; given at the dose of 1.2 mg/m(2) per day, four consecutive days as one cycle and 21 days as one course. A total of 1 - 4 courses were given according to the patient's tolerance. Four of these 21 patients also received combination of cisplatin. RESULTS: Among the 13 un-operated patients, two patients showed CR, six showed PR, three SD and two PD, giving an effective rate of 62%. Among the 8 operated patients, seven showed SD but one developed distant metastasis. The 1-year survival rate was 88%. TOXICITY: leukopenia I-II degree 14 (66.7%), leukopenia III-IV degree 5 (23.8%), thrombocytopenia III-IV degree 1 (4.8%) and one patient died of high fever and neutocytopenia. Nausea 8 (38.1%), vomiting 3 (14.3%) and diarrhea 2 (9.5%) alopecia 4 (19.1%). Were the other side-effects. CONCLUSION: Hycamtin is indicated for second line therapy for lung cancer giving tolerable toxicity.